Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Recent Advances in Onychomycosis Epidemiology, Diagnosis, and Risk Factors

Description

The talk reviews recent advances in onychomycosis, focusing on epidemiology, organism patterns, mixed infections, and high-risk groups. It notes that global prevalence is around 4% and that exposure in congregate settings like swimming pools can increase risk. Classic forms of infection are briefly reviewed, along with endonyx onychomycosis, which is characterized by fungal presence in the nail plate without typical nail bed inflammation or hyperkeratosis and has been reported mainly in Asia and Africa. Newer molecular and histopathologic approaches show important epidemiologic shifts: while dermatophytes remain the commonest causes, non-dermatophyte molds such as Aspergillus and Fusarium are increasingly recognized, and females may be about twice as likely as males to have non-dermatophyte mold onychomycosis. The speaker also highlights the complexity of Trichophyton mentagrophytes, which includes many genotypes linked to nail and skin disease. Mixed infections are common and clinically important because treatment may clear one organism while leaving the other behind, leading to failure. Special populations at higher risk include children, older adults, people with diabetes, and immunocompromised patients. Finally, onychomycosis is not always benign: in neutropenic or transplant patients, severe cases can spread systemically, so treatment before or during transplantation may be advisable, and accurate diagnostic testing to identify the causative species is essential.

View more

Conclusions

  • Distal lateral subungual onychomycosis is the most common clinical form of toenail infection, while other forms such as superficial white, endonyx, and total dystrophic disease are less frequent.
  • Endonyx onychomycosis is a distinct pattern where fungus invades the nail plate without nail-bed inflammation, hyperkeratosis, or onycholysis, and it appears to be reported mainly in Asia and Africa.
  • Overall dermatophyte onychomycosis has a global prevalence of about 4%, with higher risk in congregate settings and in older adults.
  • In U.S. molecular/pathology-based data, non-dermatophyte molds are more common in women than men, occurring at roughly twice the rate in females.
  • The main U.S. non-dermatophyte mold pathogens are Aspergillus and Fusarium, with other molds such as Neoscytalidium also contributing.
  • Trichophyton mentagrophytes is a genetically diverse complex, and certain genotypes are associated with onychomycosis, tinea pedis, sexual transmission, and terbinafine resistance.
  • Mixed infections are common, so finding a dermatophyte does not exclude a concurrent non-dermatophyte mold that may cause treatment failure if not identified.
  • Onychomycosis is more common in special populations such as patients with diabetes, immunosuppression, renal transplant, HIV, lupus, chronic venous disease, and some older adults.
  • Pediatric onychomycosis occurs less often than adult disease, but clinicians still need to consider it in children.
  • Onychomycosis should not always be considered purely cosmetic because invasive or disseminated fungal disease can occur in severely immunocompromised patients, especially with Fusarium.
  • Patients with onychomycosis who are scheduled for transplantation should be treated before or at the time of transplant to reduce risk.
  • Accurate diagnostic testing, including PCR and histopathology, is essential to confirm the diagnosis and identify the causative species so therapy can be appropriately targeted.
  • Despite the importance of testing, many cases are still under-tested, so improved diagnostic confirmation is needed in routine practice.
  • Gupta AK. et al. JEADV 2016;30(9):1567-72.
  • Tosti et al. ActaDermVenereol 1999; 79:52-53; De-La-Rosa-Garibay et al. Diseases 2025; 13:110.
  • De-La-Rosa-Garibay et al. Diseases 2025; 13:110.
  • Gupta 2024 Mycoses PMID: 38606891; Gold 2023 JAAD PMID: 35809801.
  • Gupta 2024. J Fungi. PMID: 39330393.
  • Gupta et al. 2026. Mycopathologia; 191(6).
  • Gupta et al. PLOS ONE. 2020 Sep 29;15(9):e0239648.
  • Gupta 2024 Mycoses PMID: 38606891
  • Boutati et al. Blood 1997;90(3):999-1008
  • Baran et al. BJD 2005; 153(5):1023-5.